Skip to main content
Top
Published in: CNS Drugs 8/2011

01-08-2011 | Therapy in Practice

Antipsychotic Pharmacotherapy and Orthostatic Hypotension

Identification and Management

Author: Dr James J. Gugger

Published in: CNS Drugs | Issue 8/2011

Login to get access

Abstract

Orthostatic hypotension is a common adverse effect of antipsychotics that may delay or prevent titration to a dose necessary to control psychotic symptoms. Complications of orthostatic hypotension include syncope, transient ischaemic attack, stroke, myocardial infarction and death. The risk of orthostatic hypotension associated with antipsychotic therapy is increased in patients with disorders of the autonomic nervous system, fluid imbalance and those taking concomitant drug therapy that affects haemodynamic tone. Prospective monitoring for changes in postural blood pressure is important because patients with psychotic disorders often do not articulate symptoms of orthostasis and the subjective report of dizziness does not correlate well with orthostatic blood pressure changes.
Nonpharmacological strategies and patient education, most notably, slowly rising from the supine position, are crucial first steps in the prevention and treatment of both symptomatic and asymptomatic orthostatic hypotension. Pharmacological treatment is only recommended when symptomatic orthostatic hypotension persists despite proper nonpharmacological therapy and there is a compelling indication for antipsychotic treatment. Fludrocortisone is a reasonable first choice for symptomatic orthostatic hypotension. Other agents including desmopressin and midodrine may be considered in patients who do not respond favourably to a trial of fludrocortisone, but safety concerns and lack of evidence limit the utility of these agents.
Literature
1.
go back to reference Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother 2007; 7: 829–39PubMedCrossRef Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother 2007; 7: 829–39PubMedCrossRef
2.
go back to reference Drici MD, Priori S. Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiol Drug Saf 2007; 16: 882–90PubMedCrossRef Drici MD, Priori S. Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiol Drug Saf 2007; 16: 882–90PubMedCrossRef
3.
go back to reference Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997; 58 Suppl. 10: 55–62 Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997; 58 Suppl. 10: 55–62
4.
go back to reference Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23PubMedCrossRef Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23PubMedCrossRef
5.
go back to reference Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007; 164: 415–27PubMedCrossRef Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007; 164: 415–27PubMedCrossRef
6.
go back to reference Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163: 611–22PubMedCrossRef Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163: 611–22PubMedCrossRef
7.
go back to reference McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600–10PubMedCrossRef McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600–10PubMedCrossRef
8.
go back to reference Stroup TS, Lieberman JA, McEvoy JP, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009; 107: 1–12PubMedCrossRef Stroup TS, Lieberman JA, McEvoy JP, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009; 107: 1–12PubMedCrossRef
9.
go back to reference Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2009; 63: 1237–48PubMedCrossRef Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2009; 63: 1237–48PubMedCrossRef
11.
go back to reference Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009; 63: 1762–84PubMedCrossRef Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009; 63: 1762–84PubMedCrossRef
12.
go back to reference Swett Jr C, Cole JO, Hartz SC, et al. Hypotension due to chlorpromazine: relation to cigarette smoking, blood pressure, and dosage. Arch Gen Psychiatry 1977; 34: 661–3PubMedCrossRef Swett Jr C, Cole JO, Hartz SC, et al. Hypotension due to chlorpromazine: relation to cigarette smoking, blood pressure, and dosage. Arch Gen Psychiatry 1977; 34: 661–3PubMedCrossRef
13.
go back to reference Timdahl K, Carlsson A, Stening G. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Hum Psychopharmacol 2007; 22: 315–25PubMedCrossRef Timdahl K, Carlsson A, Stening G. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Hum Psychopharmacol 2007; 22: 315–25PubMedCrossRef
14.
go back to reference Bishop MP, Gallant DM. Loxapine: a controlled evaluation in chronic schizophrenic patients. Curr Ther Res Clin Exp 1970; 12: 594–7PubMed Bishop MP, Gallant DM. Loxapine: a controlled evaluation in chronic schizophrenic patients. Curr Ther Res Clin Exp 1970; 12: 594–7PubMed
15.
go back to reference Gershon S, Hekimian LJ, Burdock EI, et al. Antipsychotic properties of loxapine succinate. Curr Ther Res Clin Exp 1970; 12: 280–5PubMed Gershon S, Hekimian LJ, Burdock EI, et al. Antipsychotic properties of loxapine succinate. Curr Ther Res Clin Exp 1970; 12: 280–5PubMed
16.
17.
go back to reference Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 2008; 23 Suppl. 1: 3–14CrossRef Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 2008; 23 Suppl. 1: 3–14CrossRef
18.
go back to reference Simpson GM, Cuculic Z. A double-blind comparison of loxapine succinate and trifluoperazine in newly admitted schizophrenic patients. J Clin Pharmacol 1976; 16: 60–5PubMed Simpson GM, Cuculic Z. A double-blind comparison of loxapine succinate and trifluoperazine in newly admitted schizophrenic patients. J Clin Pharmacol 1976; 16: 60–5PubMed
19.
go back to reference Weiden PJ, Cutler AJ, Polymeropoulos MH, et al. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008; 28(2 Suppl. 1): S12–9PubMedCrossRef Weiden PJ, Cutler AJ, Polymeropoulos MH, et al. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008; 28(2 Suppl. 1): S12–9PubMedCrossRef
21.
go back to reference Curry SH. Chlorpromazine: concentrations in plasma, excretion in urine and duration of effect. Proc R Soc Med 1971; 64: 285–9PubMed Curry SH. Chlorpromazine: concentrations in plasma, excretion in urine and duration of effect. Proc R Soc Med 1971; 64: 285–9PubMed
22.
go back to reference Chandrasena R, Dvorakova D, Lee SI, et al. Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania. Int J Clin Pract 2009; 63: 1249–58PubMed Chandrasena R, Dvorakova D, Lee SI, et al. Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania. Int J Clin Pract 2009; 63: 1249–58PubMed
23.
24.
go back to reference Ritter RM, Davidson DE, Robinson TA. Comparison of injectable haloperidol and chlorpromazine. Am J Psychiatry 1972; 129: 78–81PubMed Ritter RM, Davidson DE, Robinson TA. Comparison of injectable haloperidol and chlorpromazine. Am J Psychiatry 1972; 129: 78–81PubMed
25.
go back to reference Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy: the Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 1996; 46: 1470CrossRef Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy: the Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 1996; 46: 1470CrossRef
26.
27.
go back to reference Scalco MZ, de Almeida OP, Hachul DT, et al. Comparison of risk of orthostatic hypotension in elderly depressed hypertensive women treated with nortriptyline and thiazides versus elderly depressed normotensive women treated with nortriptyline. Am J Cardiol 2000; 85: 1156–8, A9PubMedCrossRef Scalco MZ, de Almeida OP, Hachul DT, et al. Comparison of risk of orthostatic hypotension in elderly depressed hypertensive women treated with nortriptyline and thiazides versus elderly depressed normotensive women treated with nortriptyline. Am J Cardiol 2000; 85: 1156–8, A9PubMedCrossRef
28.
go back to reference Ensrud KE, Nevitt MC, Yunis C, et al. Postural hypotension and postural dizziness in elderly women: the study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. Arch Intern Med 1992; 152: 1058–64 Ensrud KE, Nevitt MC, Yunis C, et al. Postural hypotension and postural dizziness in elderly women: the study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. Arch Intern Med 1992; 152: 1058–64
29.
go back to reference Kaplan NM. Hypotension as a complication of promazine therapy. AMA Arch Intern Med 1959; 103: 219–23PubMedCrossRef Kaplan NM. Hypotension as a complication of promazine therapy. AMA Arch Intern Med 1959; 103: 219–23PubMedCrossRef
30.
go back to reference Jefferson JW. Atypical manifestations of postural hypotension. Arch Gen Psychiatry 1972; 27: 250–1PubMedCrossRef Jefferson JW. Atypical manifestations of postural hypotension. Arch Gen Psychiatry 1972; 27: 250–1PubMedCrossRef
31.
go back to reference Rutan GH, Hermanson B, Bild DE, et al. Orthostatic hypotension in older adults: the Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension 1992; 19: 508–19 Rutan GH, Hermanson B, Bild DE, et al. Orthostatic hypotension in older adults: the Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension 1992; 19: 508–19
32.
go back to reference Rosati D. Hypotensive side effects of phenothiazine and their management. Dis Nerv Syst 1964; 25: 366–9PubMed Rosati D. Hypotensive side effects of phenothiazine and their management. Dis Nerv Syst 1964; 25: 366–9PubMed
33.
go back to reference Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987–1996. Stroke 2000; 31: 2307–13PubMedCrossRef Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987–1996. Stroke 2000; 31: 2307–13PubMedCrossRef
34.
go back to reference Masaki KH, Schatz IJ, Burchfiel CM, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation 1998; 98: 2290–5PubMedCrossRef Masaki KH, Schatz IJ, Burchfiel CM, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation 1998; 98: 2290–5PubMedCrossRef
35.
go back to reference Rose KM, Eigenbrodt ML, Biga RL, et al. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) Study. Circulation 2006; 114: 630–6PubMedCrossRef Rose KM, Eigenbrodt ML, Biga RL, et al. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) Study. Circulation 2006; 114: 630–6PubMedCrossRef
36.
go back to reference Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225–35PubMedCrossRef Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225–35PubMedCrossRef
37.
go back to reference Silver H, Kogan H, Zlotogorski D. Postural hypotension in chronically medicated schizophrenics. J Clin Psychiatry 1990; 51: 459–62PubMed Silver H, Kogan H, Zlotogorski D. Postural hypotension in chronically medicated schizophrenics. J Clin Psychiatry 1990; 51: 459–62PubMed
38.
go back to reference Smith JJ, Porth CM, Erickson M. Hemodynamic response to the upright posture. J Clin Pharmacol 1994; 34: 375–86PubMed Smith JJ, Porth CM, Erickson M. Hemodynamic response to the upright posture. J Clin Pharmacol 1994; 34: 375–86PubMed
39.
go back to reference Westfall TC, Westfall DP. Neurotransmission: the autonomic and somatic motor nervous systems. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York (NY): The McGraw-Hill Companies, Inc., 2006: 137–82 Westfall TC, Westfall DP. Neurotransmission: the autonomic and somatic motor nervous systems. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York (NY): The McGraw-Hill Companies, Inc., 2006: 137–82
40.
go back to reference Young CR, Bowers Jr MB, Mazure CM. Management ofthe adverse effects of clozapine. Schizophr Bull 1998; 24: 381–90PubMedCrossRef Young CR, Bowers Jr MB, Mazure CM. Management ofthe adverse effects of clozapine. Schizophr Bull 1998; 24: 381–90PubMedCrossRef
41.
go back to reference Tonkin AL, Wing LM. Effects of age and isolated systolic hypertension on cardiovascular reflexes. J Hypertens 1994; 12: 1083–8PubMedCrossRef Tonkin AL, Wing LM. Effects of age and isolated systolic hypertension on cardiovascular reflexes. J Hypertens 1994; 12: 1083–8PubMedCrossRef
42.
go back to reference Laitinen T, Niskanen L, Geelen G, et al. Age dependency of cardiovascular autonomic responses to head-up tilt in healthy subjects. J Appl Physiol 2004; 96: 2333–40PubMedCrossRef Laitinen T, Niskanen L, Geelen G, et al. Age dependency of cardiovascular autonomic responses to head-up tilt in healthy subjects. J Appl Physiol 2004; 96: 2333–40PubMedCrossRef
43.
go back to reference Bradley JG, Davis KA. Orthostatic hypotension. Am Fam Physician 2003; 68: 2393–8PubMed Bradley JG, Davis KA. Orthostatic hypotension. Am Fam Physician 2003; 68: 2393–8PubMed
44.
go back to reference Figueroa JJ, Basford JR, Low PA. Preventing and treating orthostatic hypotension: as easy as A, B, C. Cleve Clin J Med 2010; 77: 298–306PubMedCrossRef Figueroa JJ, Basford JR, Low PA. Preventing and treating orthostatic hypotension: as easy as A, B, C. Cleve Clin J Med 2010; 77: 298–306PubMedCrossRef
45.
go back to reference Freeman R. Current pharmacologic treatment for orthostatic hypotension. Clin Auton Res 2008; 18 Suppl. 1: 14–8CrossRef Freeman R. Current pharmacologic treatment for orthostatic hypotension. Clin Auton Res 2008; 18 Suppl. 1: 14–8CrossRef
46.
go back to reference Jordan J. Effect of water drinking on sympathetic nervous activity and blood pressure. Curr Hypertens Rep 2005; 7: 17–20PubMedCrossRef Jordan J. Effect of water drinking on sympathetic nervous activity and blood pressure. Curr Hypertens Rep 2005; 7: 17–20PubMedCrossRef
47.
go back to reference Jordan J, Shannon JR, Black BK, et al. The pressor response to water drinking in humans: a sympathetic reflex? Circulation 2000; 101: 504–9PubMedCrossRef Jordan J, Shannon JR, Black BK, et al. The pressor response to water drinking in humans: a sympathetic reflex? Circulation 2000; 101: 504–9PubMedCrossRef
48.
go back to reference Goldstein DS, Robertson D, Esler M, et al. Dysautonomias: clinical disorders of the autonomic nervous system. Ann Intern Med 2002; 137: 753–63PubMed Goldstein DS, Robertson D, Esler M, et al. Dysautonomias: clinical disorders of the autonomic nervous system. Ann Intern Med 2002; 137: 753–63PubMed
49.
go back to reference LaWall JS. Treatment of psychotropic-caused orthostatic hypotension. Psychosomatics 1980; 21: 693–4PubMed LaWall JS. Treatment of psychotropic-caused orthostatic hypotension. Psychosomatics 1980; 21: 693–4PubMed
50.
go back to reference Pirke KM. Central and peripheral noradrenalin regulation in eating disorders. Psychiatry Res 1996; 62: 43–9PubMedCrossRef Pirke KM. Central and peripheral noradrenalin regulation in eating disorders. Psychiatry Res 1996; 62: 43–9PubMedCrossRef
51.
go back to reference Kaufmann H. Treatment of patients with orthostatic hypotension and syncope. Clin Neuropharmacol 2002; 25: 133–41PubMedCrossRef Kaufmann H. Treatment of patients with orthostatic hypotension and syncope. Clin Neuropharmacol 2002; 25: 133–41PubMedCrossRef
52.
go back to reference Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 2000; 15: 201–11PubMedCrossRef Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 2000; 15: 201–11PubMedCrossRef
53.
go back to reference Weber MA. Calcium channel antagonists in the treatment of hypertension. Am J Cardiovasc Drugs 2002; 2: 415–31PubMedCrossRef Weber MA. Calcium channel antagonists in the treatment of hypertension. Am J Cardiovasc Drugs 2002; 2: 415–31PubMedCrossRef
54.
go back to reference Kranzler HR, Cardoni A. Sodium chloride treatment of antidepressant-induced orthostatic hypotension. J Clin Psychiatry 1988; 49: 366–8PubMed Kranzler HR, Cardoni A. Sodium chloride treatment of antidepressant-induced orthostatic hypotension. J Clin Psychiatry 1988; 49: 366–8PubMed
55.
go back to reference Maskall DD, Lam RW. Midodrine for TCA-induced orthostatic hypotension. J Psychiatry Neurosci 1993; 18: 276–7PubMed Maskall DD, Lam RW. Midodrine for TCA-induced orthostatic hypotension. J Psychiatry Neurosci 1993; 18: 276–7PubMed
56.
go back to reference Forster HS. Naproxen reversal of nortriptyline-induced orthostatic hypotension [letter]. J Clin Psychiatry 1989; 50: 356PubMed Forster HS. Naproxen reversal of nortriptyline-induced orthostatic hypotension [letter]. J Clin Psychiatry 1989; 50: 356PubMed
57.
go back to reference Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther 2005; 30: 173–8PubMedCrossRef Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther 2005; 30: 173–8PubMedCrossRef
58.
go back to reference Campese VM. Minoxidil: a review of its pharmacological properties and therapeutic use. Drugs 1981; 22: 257–78PubMedCrossRef Campese VM. Minoxidil: a review of its pharmacological properties and therapeutic use. Drugs 1981; 22: 257–78PubMedCrossRef
59.
go back to reference Slavachevsky I, Rachmani R, Levi Z, et al. Effect of enalapril and nifedipine on orthostatic hypotension in older hypertensive patients. J Am Geriatr Soc 2000; 48: 807–10PubMed Slavachevsky I, Rachmani R, Levi Z, et al. Effect of enalapril and nifedipine on orthostatic hypotension in older hypertensive patients. J Am Geriatr Soc 2000; 48: 807–10PubMed
60.
go back to reference Wong J, Patel RA, Kowey PR. The clinical use of angiotensin-converting enzyme inhibitors. Prog Cardiovasc Dis 2004; 47: 116–30PubMedCrossRef Wong J, Patel RA, Kowey PR. The clinical use of angiotensin-converting enzyme inhibitors. Prog Cardiovasc Dis 2004; 47: 116–30PubMedCrossRef
61.
go back to reference Thomas M, Malmcrona R, Fillmore S, et al. Haemodynamic effects of morphine in patients with acute myocardial infarction. Br Heart J 1965; 27: 863–75PubMedCrossRef Thomas M, Malmcrona R, Fillmore S, et al. Haemodynamic effects of morphine in patients with acute myocardial infarction. Br Heart J 1965; 27: 863–75PubMedCrossRef
62.
go back to reference Crawford ME, Moiniche S, Orbaek J, et al. Orthostatic hypotension during postoperative continuous thoracic epidural bupivacaine-morphine in patients undergoing abdominal surgery. Anesth Analg 1996; 83: 1028–32PubMed Crawford ME, Moiniche S, Orbaek J, et al. Orthostatic hypotension during postoperative continuous thoracic epidural bupivacaine-morphine in patients undergoing abdominal surgery. Anesth Analg 1996; 83: 1028–32PubMed
63.
go back to reference Chambers JA. The haemodynamic effects of morphine. Arch Emerg Med 1988; 5: 124–5PubMed Chambers JA. The haemodynamic effects of morphine. Arch Emerg Med 1988; 5: 124–5PubMed
64.
go back to reference Prisant LM. Phosphodiesterase-5 inhibitors and their hemodynamic effects. Curr Hypertens Rep 2006; 8: 345–51PubMedCrossRef Prisant LM. Phosphodiesterase-5 inhibitors and their hemodynamic effects. Curr Hypertens Rep 2006; 8: 345–51PubMedCrossRef
65.
go back to reference Chaudhuri KR, Maule S, Thomaides T, et al. Alcohol ingestion lowers supine blood pressure, causes splanchnic vasodilatation and worsens postural hypotension in primary autonomic failure. J Neurol 1994; 241: 145–52PubMedCrossRef Chaudhuri KR, Maule S, Thomaides T, et al. Alcohol ingestion lowers supine blood pressure, causes splanchnic vasodilatation and worsens postural hypotension in primary autonomic failure. J Neurol 1994; 241: 145–52PubMedCrossRef
66.
go back to reference Narkiewicz K, Cooley RL, Somers VK. Alcohol potentiates orthostatic hypotension: implications for alcohol-related syncope. Circulation 2000; 101: 398–402PubMedCrossRef Narkiewicz K, Cooley RL, Somers VK. Alcohol potentiates orthostatic hypotension: implications for alcohol-related syncope. Circulation 2000; 101: 398–402PubMedCrossRef
67.
go back to reference Fung HL. Biochemical mechanism of nitroglycerin action and tolerance: is this old mystery solved? Annu Rev Pharmacol Toxicol 2004; 44: 67–85PubMedCrossRef Fung HL. Biochemical mechanism of nitroglycerin action and tolerance: is this old mystery solved? Annu Rev Pharmacol Toxicol 2004; 44: 67–85PubMedCrossRef
68.
go back to reference MacMillan LB, Hein L, Smith MS, et al. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 1996; 273: 801–3PubMedCrossRef MacMillan LB, Hein L, Smith MS, et al. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 1996; 273: 801–3PubMedCrossRef
69.
go back to reference Lindqvist A, Jalonen J, Laitinen LA, et al. The effects of midazolam and ephedrine on post-exercise autonomic chronotropic control of the heart in normal subjects. Clin Auton Res 1996; 6: 343–9PubMedCrossRef Lindqvist A, Jalonen J, Laitinen LA, et al. The effects of midazolam and ephedrine on post-exercise autonomic chronotropic control of the heart in normal subjects. Clin Auton Res 1996; 6: 343–9PubMedCrossRef
70.
go back to reference van den Berg F, Tulen JH, Boomsma F, et al. Effects of alprazolam and lorazepam on catecholaminergic and cardiovascular activity during supine rest, mental load and orthostatic challenge. Psychopharmacology (Berl) 1996; 128: 21–30CrossRef van den Berg F, Tulen JH, Boomsma F, et al. Effects of alprazolam and lorazepam on catecholaminergic and cardiovascular activity during supine rest, mental load and orthostatic challenge. Psychopharmacology (Berl) 1996; 128: 21–30CrossRef
71.
go back to reference Durrieu G, Senard JM, Tran MA, et al. Effects of levodopa and bromocriptine on blood pressure and plasma catecholamines in parkinsonians. Clin Neuropharmacol 1991; 14: 84–90PubMedCrossRef Durrieu G, Senard JM, Tran MA, et al. Effects of levodopa and bromocriptine on blood pressure and plasma catecholamines in parkinsonians. Clin Neuropharmacol 1991; 14: 84–90PubMedCrossRef
72.
go back to reference Haapaniemi TH, Kallio MA, Korpelainen JT, et al. Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson’s disease. J Neurol 2000; 247: 868–74PubMedCrossRef Haapaniemi TH, Kallio MA, Korpelainen JT, et al. Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson’s disease. J Neurol 2000; 247: 868–74PubMedCrossRef
73.
go back to reference Munjack DJ. The treatment of phenelzine-induced hypotension with salt tablets: case report. J Clin Psychiatry 1984; 45: 89–90PubMed Munjack DJ. The treatment of phenelzine-induced hypotension with salt tablets: case report. J Clin Psychiatry 1984; 45: 89–90PubMed
74.
go back to reference Console AD. Controlling MAO inhibitor hypotension. Am J Psychiatry 1964; 120: 709–11PubMed Console AD. Controlling MAO inhibitor hypotension. Am J Psychiatry 1964; 120: 709–11PubMed
75.
go back to reference Robie TR. Controlling monoamine oxidase inhibitor hypotension with 9-alpha-fluoro-hydrocortisone. Am J Psychiatry 1963; 120: 170–1PubMed Robie TR. Controlling monoamine oxidase inhibitor hypotension with 9-alpha-fluoro-hydrocortisone. Am J Psychiatry 1963; 120: 170–1PubMed
76.
go back to reference Simonson M. Controlling MAO inhibitor hypotension. Am J Psychiatry 1964; 120: 1118–9PubMed Simonson M. Controlling MAO inhibitor hypotension. Am J Psychiatry 1964; 120: 1118–9PubMed
77.
go back to reference Turkka J, Suominen K, Tolonen U, et al. Selegiline diminishes cardiovascular autonomic responses in Parkinson’s disease. Neurology 1997; 48: 662–7PubMedCrossRef Turkka J, Suominen K, Tolonen U, et al. Selegiline diminishes cardiovascular autonomic responses in Parkinson’s disease. Neurology 1997; 48: 662–7PubMedCrossRef
78.
go back to reference Churchyard A, Mathias CJ, Boonkongchuen P, et al. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 63: 228–34PubMedCrossRef Churchyard A, Mathias CJ, Boonkongchuen P, et al. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 63: 228–34PubMedCrossRef
79.
go back to reference Aronow WS. Treating hypertension in older adults: safety considerations. Drug Saf 2009; 32: 111–8PubMedCrossRef Aronow WS. Treating hypertension in older adults: safety considerations. Drug Saf 2009; 32: 111–8PubMedCrossRef
80.
go back to reference Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York (NY): The McGraw-Hill Companies, Inc., 2006: 237–96 Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York (NY): The McGraw-Hill Companies, Inc., 2006: 237–96
81.
go back to reference Alexander Jr HE, McCarty K, Giffen MB. Hypotension and cardiopulmonary arrest associated with concurrent haloperidol and propranolol therapy. JAMA 1984; 252: 87–8PubMedCrossRef Alexander Jr HE, McCarty K, Giffen MB. Hypotension and cardiopulmonary arrest associated with concurrent haloperidol and propranolol therapy. JAMA 1984; 252: 87–8PubMedCrossRef
82.
go back to reference Vestal RE, Kornhauser DM, Hollifield JW, et al. Inhibition of propranolol metabolism by chlorpromazine. Clin Pharmacol Ther 1979; 25: 19–24PubMed Vestal RE, Kornhauser DM, Hollifield JW, et al. Inhibition of propranolol metabolism by chlorpromazine. Clin Pharmacol Ther 1979; 25: 19–24PubMed
83.
go back to reference Seideman P, Grahnen A, Haglund K, et al. Prazosin first dose phenomenon during combined treatment with a beta-adrenoceptor blocker in hypertensive patients. Br J Clin Pharmacol 1982; 13: 865–70PubMedCrossRef Seideman P, Grahnen A, Haglund K, et al. Prazosin first dose phenomenon during combined treatment with a beta-adrenoceptor blocker in hypertensive patients. Br J Clin Pharmacol 1982; 13: 865–70PubMedCrossRef
84.
go back to reference Raj SR, Black BK, Biaggioni I, et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation 2009; 120: 725–34PubMedCrossRef Raj SR, Black BK, Biaggioni I, et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation 2009; 120: 725–34PubMedCrossRef
85.
go back to reference Freitas J, Santos R, Azevedo E, et al. Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clin Auton Res 2000; 10: 293–9PubMedCrossRef Freitas J, Santos R, Azevedo E, et al. Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clin Auton Res 2000; 10: 293–9PubMedCrossRef
86.
go back to reference Fruncillo RJ, Gibbons WJ, Vlasses PH, et al. Severe hypotension associated with concurrent clonidine and antipsychotic medication [letter]. Am J Psychiatry 1985; 142: 274PubMed Fruncillo RJ, Gibbons WJ, Vlasses PH, et al. Severe hypotension associated with concurrent clonidine and antipsychotic medication [letter]. Am J Psychiatry 1985; 142: 274PubMed
87.
go back to reference Cantrell MA, Bream-Rouwenhorst HR, Hemerson P, et al. Silodosin for benign prostatic hyperplasia. Ann Pharmacother 2010; 44: 302–10PubMedCrossRef Cantrell MA, Bream-Rouwenhorst HR, Hemerson P, et al. Silodosin for benign prostatic hyperplasia. Ann Pharmacother 2010; 44: 302–10PubMedCrossRef
88.
go back to reference Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 2008; 15: 193–9PubMedCrossRef Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 2008; 15: 193–9PubMedCrossRef
89.
go back to reference Aronowitz JS, Chakos MH, Safferman AZ, et al. Syncope associated with the combination of clozapine and enalapril. J Clin Psychopharmacol 1994; 14: 429–30PubMedCrossRef Aronowitz JS, Chakos MH, Safferman AZ, et al. Syncope associated with the combination of clozapine and enalapril. J Clin Psychopharmacol 1994; 14: 429–30PubMedCrossRef
90.
go back to reference White WB. Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril. Arch Intern Med 1986; 146: 1833–4PubMedCrossRef White WB. Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril. Arch Intern Med 1986; 146: 1833–4PubMedCrossRef
92.
go back to reference Pae CU, Kim JJ, Lee CU, et al. Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial. J Clin Psychiatry 2007; 68: 399–405PubMedCrossRef Pae CU, Kim JJ, Lee CU, et al. Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial. J Clin Psychiatry 2007; 68: 399–405PubMedCrossRef
93.
go back to reference Boidi G, Ferro M. Rapid dose initiation of quetiapine for the treatment of acute schizophrenia and schizoaffective disorder: a randomised, multicentre, parallel-group, open study. Hum Psychopharmacol 2007; 22: 299–306PubMedCrossRef Boidi G, Ferro M. Rapid dose initiation of quetiapine for the treatment of acute schizophrenia and schizoaffective disorder: a randomised, multicentre, parallel-group, open study. Hum Psychopharmacol 2007; 22: 299–306PubMedCrossRef
94.
go back to reference Smith MA, McCoy R, Hamer-Maansson J, et al. Rapid dose escalation with quetiapine: a pilot study. J Clin Psychopharmacol 2005; 25: 331–5PubMedCrossRef Smith MA, McCoy R, Hamer-Maansson J, et al. Rapid dose escalation with quetiapine: a pilot study. J Clin Psychopharmacol 2005; 25: 331–5PubMedCrossRef
95.
go back to reference Baker RW, Kinon BJ, Maguire GA, et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003; 23: 342–8PubMedCrossRef Baker RW, Kinon BJ, Maguire GA, et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003; 23: 342–8PubMedCrossRef
96.
go back to reference Karagianis JL, Dawe IC, Thakur A, et al. Rapid tranquilization with olanzapine in acute psychosis: a case series. J Clin Psychiatry 2001; 62 Suppl. 2: 12–6 Karagianis JL, Dawe IC, Thakur A, et al. Rapid tranquilization with olanzapine in acute psychosis: a case series. J Clin Psychiatry 2001; 62 Suppl. 2: 12–6
97.
go back to reference Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry 2000; 61: 909–11PubMedCrossRef Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry 2000; 61: 909–11PubMedCrossRef
98.
go back to reference Chengappa KN, Parepally H, Brar JS, et al. A randomassignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study. Can J Psychiatry 2003; 48: 187–94PubMed Chengappa KN, Parepally H, Brar JS, et al. A randomassignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study. Can J Psychiatry 2003; 48: 187–94PubMed
99.
go back to reference Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 199–204PubMedCrossRef Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 199–204PubMedCrossRef
100.
go back to reference Testani Jr M. Clozapine-induced orthostatic hypotension treated with fludrocortisone. J Clin Psychiatry 1994; 55: 497–8PubMed Testani Jr M. Clozapine-induced orthostatic hypotension treated with fludrocortisone. J Clin Psychiatry 1994; 55: 497–8PubMed
101.
go back to reference Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York (NY): The McGraw-Hill Companies, Inc., 2006: 1587–612 Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York (NY): The McGraw-Hill Companies, Inc., 2006: 1587–612
102.
go back to reference Mathias CJ, Fosbraey P, da Costa DF, et al. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br Med J (Clin Res Ed) 1986; 293: 353–4CrossRef Mathias CJ, Fosbraey P, da Costa DF, et al. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br Med J (Clin Res Ed) 1986; 293: 353–4CrossRef
103.
go back to reference Stumpf JL, Mitrzyk B. Management of orthostatic hypotension. Am J Hosp Pharm 1994; 51: 648–60; quiz 697-8PubMed Stumpf JL, Mitrzyk B. Management of orthostatic hypotension. Am J Hosp Pharm 1994; 51: 648–60; quiz 697-8PubMed
104.
go back to reference Sarma S, Ward W, O’Brien J, et al. Severe hyponatraemia associated with desmopressin nasal spray to treat clozapine-induced nocturnal enuresis [letter]. Aust N Z J Psychiatry 2005; 39: 949PubMedCrossRef Sarma S, Ward W, O’Brien J, et al. Severe hyponatraemia associated with desmopressin nasal spray to treat clozapine-induced nocturnal enuresis [letter]. Aust N Z J Psychiatry 2005; 39: 949PubMedCrossRef
105.
go back to reference Castrioto A, Tambasco N, Rossi A, et al. Acute dystonia induced by the combination of midodrine and perphenazine. J Neurol 2008; 255: 767–8PubMedCrossRef Castrioto A, Tambasco N, Rossi A, et al. Acute dystonia induced by the combination of midodrine and perphenazine. J Neurol 2008; 255: 767–8PubMedCrossRef
106.
go back to reference Takahashi H. Acute dystonia induced by adding midodrine, a selective alpha 1 agonist, to risperidone in a patient with catatonic schizophrenia. J Neuropsychiatry Clin Neurosci 2000; 12: 285–6PubMedCrossRef Takahashi H. Acute dystonia induced by adding midodrine, a selective alpha 1 agonist, to risperidone in a patient with catatonic schizophrenia. J Neuropsychiatry Clin Neurosci 2000; 12: 285–6PubMedCrossRef
Metadata
Title
Antipsychotic Pharmacotherapy and Orthostatic Hypotension
Identification and Management
Author
Dr James J. Gugger
Publication date
01-08-2011
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 8/2011
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/11591710-000000000-00000

Other articles of this Issue 8/2011

CNS Drugs 8/2011 Go to the issue

Adis Drug Evaluation

Fingolimod

Adis Drug Evaluation

Rotigotine Transdermal Patch